261762-59-8|2-Chloro-5-fluorobenzyl alcohol| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 261762-59-8 ] Purity: 97% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 261762-59-8 ]

CAS No. :	261762-59-8
Formula :	C₇H₆ClFO
M.W :	160.57
SMILES Code :	OCC1=C(Cl)C=CC(F)=C1
MDL No. :	MFCD01631418
InChI Key :	VTZKFYRHXVQMQL-UHFFFAOYSA-N
Pubchem ID :	2773605

Safety of [ 261762-59-8 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 261762-59-8 ] Show Less

Physicochemical Properties

Num. heavy atoms	10
Num. arom. heavy atoms	6
Fraction Csp3	0.14
Num. rotatable bonds	1
Num. H-bond acceptors	2.0
Num. H-bond donors	1.0
Molar Refractivity	37.54
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	20.23 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.92
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	1.34
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	2.24
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	2.57
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	2.74
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	2.16

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-2.06
Solubility	1.41 mg/ml ; 0.00875 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-1.37
Solubility	6.9 mg/ml ; 0.043 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-3.11
Solubility	0.124 mg/ml ; 0.000774 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.33 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	2.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.27

Application In Synthesis of [ 261762-59-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 261762-59-8 ]

[ 261762-59-8 ] Synthesis Path-Downstream 1~16

1
[ 261762-59-8 ]
[ 1231251-50-5 ]
[ 1231251-51-6 ]

Yield	Reaction Conditions	Operation in experiment
59%	With di-isopropyl azodicarboxylate; triphenylphosphine; In dichloromethane;Inert atmosphere;	Conversion 4, step 4C; Preparation of 5-(2-chloro-5-fluoro-benzyloxy)-3-{4-(4-methyl-piperazin-1-yl)-2-[(tetrahydro-pyran-4-yl)-(2,2,2- trifluoro-acetylj-aminol-benzoylaminoj-indazole-i-carboxylic acid tert-butyl ester; Triphenylphosphine (146 mg, 0.557 mmol) in DCM (2 mL), cooled at 4C, in a nitrogen atmosphere was treated with neat diisopropyl azodicarboxylate (0.106 mL, 0.5208 mmol) while stirring. After 20 minutes the colourless solution was treated with 5-hydroxy-3-{4-(4-methyl-piperazin-1-yl)-2-[(tetrahydro-pyran-4-yl)-(2,2,2-trifluoro-acetyl)-amino]- benzoylamino}-indazole-1-carboxylic acid tert-butyl ester (82 mg, 0.5108 mmol) in DCM (2 mL). After 2 hours the crude was purified by flash chromatography over silica gel (DCM:EtOH:35% NH4OH 95:5:0.5) and 108 mg of title compound were obtained as a white solid in 59 % yield. ESI(+) MS: m/z 790 (MH+).

References: [1]Patent: WO2010/69966,2010,A1 .Location in patent: Page/Page column 56.

2
[ 261762-59-8 ]
[ 1292850-25-9 ]

References: [1]Bioorganic and Medicinal Chemistry,2011,vol. 19,p. 1930 - 1949.

3
[ 261762-59-8 ]
[ 1292850-26-0 ]

References: [1]Bioorganic and Medicinal Chemistry,2011,vol. 19,p. 1930 - 1949.

4
[ 261762-59-8 ]
[ 84194-30-9 ]

Yield	Reaction Conditions	Operation in experiment
1.33 g		The solution of 2-chloro-5-fluoro-benzoic acid (4.00 g, 23.0 mmol) in THE (200 ml) was added triethylamine (4.14 ml, 29.9 mmol). At -30 C, the mixture was added ethyl chloroformate (2.62 ml, 27.8 mmol) and stirred for 10 min. The solution was added sodium borohydrate (2.60 g, 68.9 mmol) and stirred for 5 min. The mixture was added H2O (10 ml) and stirred for 20 min at room temperature. The solution was concentrated in vacuo and the residue was added CHCl3 and 1 N HClaq. The organic layer was washed with 1 N NaOHaq and dried over Na2SO4. The solution was removed in reduced pressure. The residue was washed with n-hexane to give alcohol as a colorless solid. To the CH2Cl2 suspention of dimethylsulfoxide (2.43 ml, 34.2 mmol) was added a solution of oxalyl chloride (1.47 ml, 17.1 mmol) in 50 ml of dry CH2Cl2 at -78 C, and the resulting mixture was stirred for 20 min. CH2Cl2 (15 ml) solution of the alcohol was added at -78 C. The mixture was allowed to warm to -40 C for 1 h. The mixture was added triethylamine (7.89 ml, 57.0 mmol), allowed to warm to room temperature, and was treated with 0.1 N HClaq. The organic layer was washed with saturated Na2CO3aq, dried over Na2SO4, and concentrated in vacuo to give the title compound (1.33 g, 37%) as a colorless solid after trituration with n-hexane. 1H NMR (400 MHz, CDCl3) delta 7.22-7.28 (1H, m), 7.41-7.47 (1H, m), 7.58-7.64 (1H, m), 10.42 (1H, d, J = 3.2 Hz). MS (EI) m/z 158 M+.

References: [1]Bioorganic and Medicinal Chemistry,2011,vol. 19,p. 1930 - 1949.

5
[ 2252-50-8 ]
[ 261762-59-8 ]

Yield	Reaction Conditions	Operation in experiment
		The solution of 2-chloro-5-fluoro-benzoic acid (4.00 g, 23.0 mmol) in THE (200 ml) was added triethylamine (4.14 ml, 29.9 mmol). At -30 C, the mixture was added ethyl chloroformate (2.62 ml, 27.8 mmol) and stirred for 10 min. The solution was added sodium borohydrate (2.60 g, 68.9 mmol) and stirred for 5 min. The mixture was added H2O (10 ml) and stirred for 20 min at room temperature. The solution was concentrated in vacuo and the residue was added CHCl3 and 1 N HClaq. The organic layer was washed with 1 N NaOHaq and dried over Na2SO4. The solution was removed in reduced pressure. The residue was washed with n-hexane to give alcohol as a colorless solid. To the CH2Cl2 suspention of dimethylsulfoxide (2.43 ml, 34.2 mmol) was added a solution of oxalyl chloride (1.47 ml, 17.1 mmol) in 50 ml of dry CH2Cl2 at -78 C, and the resulting mixture was stirred for 20 min. CH2Cl2 (15 ml) solution of the alcohol was added at -78 C. The mixture was allowed to warm to -40 C for 1 h. The mixture was added triethylamine (7.89 ml, 57.0 mmol), allowed to warm to room temperature, and was treated with 0.1 N HClaq. The organic layer was washed with saturated Na2CO3aq, dried over Na2SO4, and concentrated in vacuo to give the title compound (1.33 g, 37%) as a colorless solid after trituration with n-hexane. 1H NMR (400 MHz, CDCl3) delta 7.22-7.28 (1H, m), 7.41-7.47 (1H, m), 7.58-7.64 (1H, m), 10.42 (1H, d, J = 3.2 Hz). MS (EI) m/z 158 M+.

References: [1]Bioorganic and Medicinal Chemistry,2011,vol. 19,p. 1930 - 1949.
[2]Patent: US2011/160212,2011,A1 .

6
[ 647020-63-1 ]
[ 261762-59-8 ]

Yield	Reaction Conditions	Operation in experiment
	With methanol; sodium tetrahydroborate; at 20℃; for 1h;	To a solution of methyl 2-chloro-5-fluorobenzoate (23, 35.0 g, 185.6 mmol) in dry THF (150 mL) was added NaBH4 (21.2 g, 557 mmol). Methanol (40 mL) was added dropwise at RT. After the addition, the mixture was stirred at RT for 1 h. Water (300 mL) was slowly added. The mixture was extracted with CH2Cl2 (200 mL×2). The combined extracts were washed with saturated NaHCO3 and brine, dried over MgSO4, and concentrated to give (2-chloro-5-fluorophenyl)methanol (24).

References: [1]Patent: US2011/160212,2011,A1 .Location in patent: Page/Page column 23.

7
[ 261762-59-8 ]
[ 81778-09-8 ]